MABLINK BIOSCIENCE

MABLINK BIOSCIENCE est membre de Lyonbiopôle

General information

14 rue Waldeck Rousseau

69006 Lyon

Incorporated in: 2018/12/05

Number of employees: 5


More information

 

Main activity

Mablink Bioscience is a biotechnology company developping next-generation Antibody-Drug-Conjugates (ADC) based on a proprietary drug-linker platform technology. Its drug-linker technology delivers ADCs with a high payload (DAR of 8-16) that are homogeneous and plasma-stable,without negative impact on aggregation, with improved pharmacokinetics, in a timely and cost-effective manner. With its technology platform, Mablink is democratizing the use of next-generation ADC in the clinic, to improve patient care in the immuno-oncolgy field.


Funding

Looking for funding: Yes

Private funding obtained: Investissement innovation PULSALYS (2019)

Public funding obtained: Concours innovation (2019, i-Lab) Programme OncoStarter AAP10 (2017, CLARA) Bourse French Tech (2016, BPI)

Segmentation
Activities
Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine


Application market
Oncology


Activities
Therapeutics, Pharma or Biotech - Technology provider


Technologies
Chemical synthesis services & medicinale chemistry - Antibodies - Protein - Peptide - Others